Vivos Therapeutics Financials - Benzinga

Vivos Therapeutics Inc

VVOSNASDAQ

Trade with Public

Trade with Public

$0.1778

-0.0062-3.37%

Last update: Sep 14, 12:19 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Vivos Therapeutics Financials

Vivos Therapeutics (VVOS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 43.64 percent increase over losses of $(0.55) per share

Benzinga Newsdesk

PRO
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.45) by 15.56 percent. This is a 15.56 percent decrease over losses of $(0.45) per share

Benzinga Newsdesk

PRO
Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 107.14 percent decrease over losses of $(0.28) per share

Benzinga Newsdesk

Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday

U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.

Avi Kapoor

PRO
Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share

Benzinga Newsdesk

PRO
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share

Benzinga Newsdesk